肿瘤细胞治疗研究
英文原题：The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence.
The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
原发性骨肿瘤（PBT）虽较罕见，但由于肺转移发生率高，可能导致显著死亡和患病负担。PBT 患者生存率因肿瘤类型、治疗干预和诊断时机而异。尽管过去 40 年患者管理已有进展，生存率似乎未显著改善，提示亟需新的治疗干预。广泛切缘手术切除、放疗和全身化疗是 PBT 的主要治疗方式。新辅助及辅助化疗，以及嵌合抗原受体（CAR）T 细胞治疗等新兴免疫治疗方法，有望改善 PBT 患者的治疗结局。CAR-T 细胞治疗已用于血液系统恶性肿瘤，FDA 已批准多种靶向 CD19 的 CAR-T 产品。本综述旨在强调免疫治疗策略，尤其是 CAR-T 细胞治疗在 PBT 管理中的潜力。
Primary bone tumors (PBT), although rare, could pose significant mortality and morbidity risks due to their high incidence of lung metastasis. Survival rates of patients with PBTs may vary based on the tumor type, therapeutic interventions, and the time of diagnosis. Despite advances in the management of patients with these tumors over the past four decades, the survival rates seem not to have improved significantly, implicating the need for novel therapeutic interventions. Surgical resection with wide margins, radiotherapy, and systemic chemotherapy are the main lines of treatment for PBTs.
Neoadjuvant and adjuvant chemotherapy, along with emerging immunotherapeutic approaches such as chimeric antigen receptor (CAR)-T cell therapy, have the potential to improve the treatment outcomes for patients with PBTs. CAR-T cell therapy has been introduced as an option in hematologic malignancies, with FDA approval for several CD19-targeting CAR-T cell products. This review aims to highlight the potential of immunotherapeutic strategies, specifically CAR T cell therapy, in managing PBTs.
MEMBER ACCOUNT
登录成功会直接打开下一页。
